Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma

Project Summary Title and Description

Title
Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma
Description
Systematic review of imaging tests for diagnosis, staging, and/or screening of pancreatic adenocarcinoma
Attribution
N/A
Authors of Report
N/A
Methodology description
EPC report
PROSPERO
N/A
DOI
10.7301/Z0RF5RZX
Notes
Below is the correspondence between the Key Question numbering in the actual report and the Key Question numbering on SRDR . 1 on SRDR is 1a in the report. 2 on SRDR is 1b through 1g in the report. 3 on SRDR is 2a in the report. 4 on SRDR is 2b through 2g in the report. 5 on SRDR is 3 and 3a in the report. 6 on SRDR is 3b in the report. 7 on SRDR is 4 in the report. ** The systematic review data of this published project was retrospectively imported into SRDR by the ECRI Institute-Penn Medicine EPC Brown EPC on behalf of the the Agency for Healthcare Research and Quality (AHRQ). For access to the full report available on the AHRQ website, follow this link: http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=1972 **
Funding Source
AHRQ

Key Questions

1. What is the comparative effectiveness of imaging techniques (e.g., MDCT, MDCT angiography, EUS-FNA, PET/CT, MRI) for diagnosis of pancreatic adenocarcinoma in adults with suspicious symptoms? a. What is the accuracy of each imaging technique for diagnosis and assessment of resectability?
2. What is the comparative effectiveness of imaging techniques (e.g., MDCT, MDCT angiography, EUS-FNA, PET/CT, MRI) for diagnosis of pancreatic adenocarcinoma in adults with suspicious symptoms? b. What is the comparative accuracy of the different imaging techniques for diagnosis and assessment of resectability? c. What is the comparative diagnostic accuracy of using a single imaging technique versus using multiple imaging techniques? d. How is test experience (e.g., operative experience, assessor experience, center’s annual case volume) related to comparative diagnostic accuracy of the different imaging strategies? e. How are patient factors and tumor characteristics related to the comparative diagnostic accuracy of the different imaging strategies? f. What is the comparative clinical management after the different imaging strategies when used for diagnosis? g. What is the comparative impact of the different imaging strategies on long-term survival and quality of life when used for diagnosis?
3. What is the comparative effectiveness of imaging techniques (e.g., MDCT, MDCT angiography, EUS-FNA, PET/CT, MRI) for staging of pancreatic adenocarcinoma among adults with a diagnosis of pancreatic adenocarcinoma? a. What is the staging accuracy of each imaging technique (for tumor size, lymph node status, vessel involvement, metastases, stage I–IV, and resectability)?
4. What is the comparative effectiveness of imaging techniques (e.g., MDCT, MDCT angiography, EUS-FNA, PET/CT, MRI) for staging of pancreatic adenocarcinoma among adults with a diagnosis of pancreatic adenocarcinoma? b. What is the comparative staging accuracy among the different imaging techniques? c. What is the comparative staging accuracy of using a single imaging technique versus using multiple imaging techniques? d. How is test experience (e.g., operative experience, assessor experience, center’s annual volume) related to comparative staging accuracy of the different imaging strategies? e. How are patient factors and tumor characteristics related to the comparative staging accuracy of the different imaging strategies? f. What is the comparative clinical management of the different imaging strategies when used for staging? g. What is the comparative impact of the different imaging strategies on long-term survival and quality of life when used for staging?
5. What are the rates of harms of imaging techniques (e.g., MDCT, MDCT angiography, EUS-FNA, PET/CT, MRI) when used to diagnose and/or stage pancreatic adenocarcinoma? a. How are patient factors related to the harms of different imaging techniques? b. What are patient perspectives on the tolerance of different imaging techniques and the balance of benefits and harms of different imaging techniques?
6. What is the screening accuracy of imaging techniques (e.g., MDCT, MDCT angiography, EUS-FNA, PET/CT, MRI) for detecting precursor lesion(s) of pancreatic cancer or pancreatic adenocarcinoma in high-risk asymptomatic adults (i.e., those at genetic or familial risk of pancreatic adenocarcinoma)?

Associated Extraction Forms

Downloadable Data Content

Files
  • XLSX Project Data